Helus Pharma Inc. (FRA:R7E0)
Germany · Delayed Price · Currency is EUR | Market Cap | 769.95M +467.1% |
| Revenue (ttm) | n/a |
| Net Income | -149.85M |
| EPS | -3.54 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300 |
| Open | 9.24 |
| Previous Close | 9.23 |
| Day's Range | 9.24 - 9.24 |
| 52-Week Range | 3.08 - 13.36 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Helus Pharma
Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’s preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat centr... [Read more]
News
Helus Pharma to Host Investor Presentation on October 21, 2026
NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds ...
Helus Pharma Slides: Corporate presentation
Helus Pharma has posted slides in relation to its latest quarterly earnings report, which was published on October 7, 2026.
Helus Pharma announces completion of legal name change
Helus Pharma (HELP) announces the Company’s legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at…
Helus Pharma Announces Completion of Legal Name Change
NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal ...
Helus Pharma Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
The summit highlighted late-stage development of deuterated psilocin for adjunctive MDD, with a phase III readout expected in Q4 2026 and NDA filing in 2028. The program aims for strong efficacy, durability, and safety advantages over current adjunctive therapies.
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developin...
Helus Pharma Transcript: AGM 2026
The AGM covered financial results, auditor appointment, board elections, and a special resolution to change the company name. All voting was conducted virtually, with results to be published post-meeting.
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT
Helus Pharma presents new analyses on HLP003 in MDD
Helus Pharma (HELP) announced the presentation of four posters evaluating HLP003 at Psych Congress 2026, September 15-19, 2026, at the Ernest Morial Convention Center in New Orleans, Louisiana. Three ...
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK ...
Helus Pharma selloff Friday a buying opportunity, says Barclays
Barclays views the selloff Friday in shares of Helus Pharma (HELP) as a buying opportunity. The firm initiated the stock on Friday morning with an Overweight rating and $35 price…
Helus Pharma initiated with an Overweight at Barclays
Barclays initiated coverage of Helus Pharma (HELP) with an Overweight rating and $35 price target
Helus Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing a late-stage program for adjunctive MDD with phase III data expected in Q4, supported by strong phase II results and FDA breakthrough designation. Additional programs target anxiety and early-stage mental health indications, with a focus on execution and scalable growth. The sector is seeing increased validation and interest from large pharma.
Helus Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is advancing a robust neuropsychiatry pipeline, with lead candidate HLP003 in phase III for adjunctive MDD and top-line data expected in Q4 2026. Strong phase II results, a supportive regulatory environment, and a solid financial position underpin plans for NDA filing and potential approval in 2028.
Helus Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Leadership highlighted deep CNS and psychiatry expertise, with a focus on novel serotonergic agonists for mental health. CYB-003 is in phase III for adjunctive MDD, with top-line data due Q4 and NDA filing targeted for 2028. CYB-004 advances in anxiety, and infrastructure is scaling for commercialization.
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT. CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:3...
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. ...
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m....
Helus Pharma price target raised to $62 from $8 at TD Cowen
TD Cowen raised the firm’s price target on Helus Pharma (HELP) to $62 from $8 and keeps a Buy rating on the shares. The firm said its target increase is…
Helus Pharma appoints Regina Donohue as chief people officer
Helus Pharma (HELP) announced the appointment of Regina Donohue as chief people officer. Most recently, at Intra-Cellular, Donohue served as chief human resources officer, where she built the company’...
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
Former Intra-Cellular Therapies, Inc. (“Intra-Cellular”) executives bring complementary experience in organizational scale-up, central nervous system (“CNS”) drug development, regulatory approvals and...
Helus Pharma Earnings release: Q1 2027
Helus Pharma released its Q1 2027 earnings on August 14, 2026, summarizing the period's financial results.
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -
Helus Pharma Transcript: Canaccord Genuity's 46th Annual Growth Conference
A new CEO with deep CNS experience is leading a platform-focused mental health company, emphasizing execution and team alignment. Lead candidate HLP003 is in phase III for adjunctive major depressive disorder, with strong phase II results and a differentiated, patent-protected profile. Top-line data is expected in Q4.
Helus Pharma appoints Michael Halstead as CEO
Helus Pharma (HELP) announced Monday the appointment of Michael Halstead as CEO. Halstead brings 25 years of industry experience, most recently serving as President of Intra-Cellular Therapies (ITCI)....